Patents by Inventor Marc R Morra
Marc R Morra has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11518804Abstract: Methods are disclosed for treating osteoarthritis in a human subject in need thereof, comprising administering to the subject a therapeutically effective amount of an anti-human NGF antibody, or antigen-binding fragment thereof, wherein at least one symptom associated with osteoarthritis is prevented, ameliorated or improved.Type: GrantFiled: July 10, 2020Date of Patent: December 6, 2022Assignee: REGENERON PHARMACEUTICALS, INC.Inventors: Lynn MacDonald, Richard Torres, Marc R. Morra, Joel H. Martin, Joel C. Reinhardt, Paul Tiseo
-
Publication number: 20200339672Abstract: Methods are disclosed for treating osteoarthritis in a human subject in need thereof, comprising administering to the subject a therapeutically effective amount of an anti-human NGF antibody, or antigen-binding fragment thereof, wherein at least one symptom associated with osteoarthritis is prevented, ameliorated or improved.Type: ApplicationFiled: July 10, 2020Publication date: October 29, 2020Applicant: REGENERON PHARMACEUTICALS, INC.Inventors: Lynn MACDONALD, Richard TORRES, Marc R. MORRA, Joel H. MARTIN, Joel C. REINHARDT, Paul TISEO
-
Patent number: 10745471Abstract: Methods are disclosed for treating osteoarthritis in a human subject in need thereof, comprising administering to the subject a therapeutically effective amount of an anti-human NGF antibody, or antigen-binding fragment thereof, wherein at least one symptom associated with osteoarthritis is prevented, ameliorated or improved.Type: GrantFiled: February 21, 2019Date of Patent: August 18, 2020Assignee: REGENERON PHARMACEUTICALS, INC.Inventors: Lynn MacDonald, Richard Torres, Marc R. Morra, Joel H. Martin, Joel C. Reinhardt, Paul Tiseo
-
Patent number: 10513557Abstract: The present invention provides antibodies and antigen-binding fragments thereof that specifically bind to cells expressing acid-sensing ion channel-1 (ASIC1). According to certain embodiments of the invention, the antibodies inhibit acid-induced, ASIC1-mediated ion currents in cells expressing human ASIC1. The antibodies of the invention are useful for the treatment of pain, including pain associated with surgical intervention and various diseases and disorders.Type: GrantFiled: September 28, 2017Date of Patent: December 24, 2019Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Lynn MacDonald, Min Gao, Marc R. Morra, Nicole M. Alessandri-Haber, Michael L. LaCroix-Fralish
-
Publication number: 20190211090Abstract: Methods are disclosed for treating osteoarthritis in a human subject in need thereof, comprising administering to the subject a therapeutically effective amount of an anti-human NGF antibody, or antigen-binding fragment thereof, wherein at least one symptom associated with osteoarthritis is prevented, ameliorated or improved.Type: ApplicationFiled: February 21, 2019Publication date: July 11, 2019Applicant: REGENERON PHARMACEUTICALS, INC.Inventors: Lynn MACDONALD, Richard TORRES, Marc R. MORRA, Joel H. MARTIN, Joel C. REINHARDT, Paul TISEO
-
Patent number: 10266588Abstract: Methods are disclosed for treating osteoarthritis in a human subject in need thereof, comprising administering to the subject a therapeutically effective amount of an anti-human NGF antibody, or antigen-binding fragment thereof, wherein at least one symptom associated with osteoarthritis is prevented, ameliorated or improved.Type: GrantFiled: May 2, 2016Date of Patent: April 23, 2019Assignee: REGENERON PHARMACEUTICALS, INC.Inventors: Lynn MacDonald, Richard Torres, Marc R. Morra, Joel H. Martin, Joel C. Reinhardt, Paul Tiseo
-
Publication number: 20180222976Abstract: The present invention provides antibodies and antigen-binding fragments thereof that specifically bind to cells expressing acid-sensing ion channel-1 (ASIC1). According to certain embodiments of the invention, the antibodies inhibit acid-induced, ASIC1-mediated ion currents in cells expressing human ASIC1. The antibodies of the invention are useful for the treatment of pain, including pain associated with surgical intervention and various diseases and disorders.Type: ApplicationFiled: September 28, 2017Publication date: August 9, 2018Inventors: Lynn MacDonald, Min Gao, Marc R. Morra, Nicole M. Alessandri-Haber, Michael L. LaCroix-Fralish
-
Publication number: 20160237148Abstract: Methods are disclosed for treating osteoarthritis in a human subject in need thereof, comprising administering to the subject a therapeutically effective amount of an anti-human NGF antibody, or antigen-binding fragment thereof, wherein at least one symptom associated with osteoarthritis is prevented, ameliorated or improved.Type: ApplicationFiled: May 2, 2016Publication date: August 18, 2016Applicant: REGENERON PHARMACEUTICALS, INC.Inventors: Lynn MACDONALD, Richard TORRES, Marc R. MORRA, Joel H. MARTIN, Joel C. REINHARDT, Paul TISEO
-
Patent number: 9371383Abstract: The present invention provides antibodies and antigen-binding fragments thereof that specifically bind to cells expressing acid-sensing ion channel-1 (ASIC1). According to certain embodiments of the invention, the antibodies inhibit acid-induced, ASIC1-mediated ion currents in cells expressing human ASIC1. According to certain embodiments, the antibodies of the invention are selective for ASIC1 and do not bind other acid-sensing ion channels in the absence of ASIC1. The antibodies of the invention are useful for the treatment of pain, including pain associated with surgical intervention and various diseases and disorders.Type: GrantFiled: October 31, 2013Date of Patent: June 21, 2016Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Lynn MacDonald, Min Gao, Marc R. Morra, Nicole M. Alessandri-Haber, Michael L. LaCroix-Fralish
-
Patent number: 9353176Abstract: Methods are disclosed for treating osteoarthritis in a human subject in need thereof, comprising administering to the subject a therapeutically effective amount of an anti-human NGF antibody, or antigen-binding fragment thereof, wherein at least one symptom associated with osteoarthritis is prevented, ameliorated or improved.Type: GrantFiled: September 26, 2013Date of Patent: May 31, 2016Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Lynn MacDonald, Richard Torres, Marc R. Morra, Joel H. Martin, Joel C. Reinhardt, Paul Tiseo
-
Publication number: 20160002332Abstract: The present invention provides antibodies and antigen-binding fragments thereof that specifically bind to cells expressing acid-sensing ion channel-1 (ASIC1). According to certain embodiments of the invention, the antibodies inhibit acid-induced, ASIC1-mediated ion currents in cells expressing human ASIC1. The antibodies of the invention are useful for the treatment of pain, including pain associated with surgical intervention and various diseases and disorders.Type: ApplicationFiled: September 9, 2015Publication date: January 7, 2016Inventors: Lynn MacDonald, Min Gao, Marc R. Morra, Nicole M. Alessandri-Haber, Michael L. LaCroix-Fralish
-
Patent number: 9150648Abstract: The present invention provides antibodies and antigen-binding fragments thereof that specifically bind to cells expressing acid-sensing ion channel-1 (ASIC1). According to certain embodiments of the invention, the antibodies inhibit acid-induced, ASIC1-mediated ion currents in cells expressing human ASIC1. The antibodies of the invention are useful for the treatment of pain, including pain associated with surgical intervention and various diseases and disorders.Type: GrantFiled: January 30, 2013Date of Patent: October 6, 2015Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Lynn MacDonald, Min Gao, Marc R. Morra, Nicole M. Alessandri-Haber, Michael L. LaCroix-Fralish
-
Methods of alleviating itch by administering human antibodies to human protease-activated receptor 2
Patent number: 9028819Abstract: The present invention provides antibodies that bind to protease-activated receptor-2 (PAR-2) and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human PAR-2. The antibodies of the invention are useful, inter alia, for the treatment of diseases and disorders associated with one or more PAR-2 biological activities, including the treatment of pain conditions, inflammatory conditions and gastrointestinal conditions.Type: GrantFiled: March 26, 2013Date of Patent: May 12, 2015Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Lynn MacDonald, Andrew J. Murphy, Nicholas J. Papadopoulos, Marc R. Morra, Robert R. Salzler, Michael L. LaCroix-Fralish -
Publication number: 20140220023Abstract: Methods are disclosed for treating osteoarthritis in a human subject in need thereof, comprising administering to the subject a therapeutically effective amount of an anti-human NGF antibody, or antigen-binding fragment thereof, wherein at least one symptom associated with osteoarthritis is prevented, ameliorated or improved.Type: ApplicationFiled: September 26, 2013Publication date: August 7, 2014Applicant: REGENERON PHARMACEUTICALS, INC.Inventors: LYNN MACDONALD, RICHARD TORRES, MARC R. MORRA, JOEL H. MARTIN, JOEL C. REINHARDT, PAUL TISEO
-
Publication number: 20140056907Abstract: The present invention provides antibodies and antigen-binding fragments thereof that specifically bind to cells expressing acid-sensing ion channel-1 (ASIC1). According to certain embodiments of the invention, the antibodies inhibit acid-induced, ASIC1-mediated ion currents in cells expressing human ASIC1. According to certain embodiments, the antibodies of the invention are selective for ASIC1 and do not bind other acid-sensing ion channels in the absence of ASIC1. The antibodies of the invention are useful for the treatment of pain, including pain associated with surgical intervention and various diseases and disorders.Type: ApplicationFiled: October 31, 2013Publication date: February 27, 2014Applicant: REGENERON PHARMACEUTICALS, INC.Inventors: Lynn MACDONALD, Min GAO, Marc R. MORRA, Nicole M. ALESSANDRI-HABER, Michael L. LaCROIX-FRALISH
-
Patent number: 8637031Abstract: Methods are disclosed for treating osteoarthritis in a human subject in need thereof, comprising administering to the subject a therapeutically effective amount of an anti-human NGF antibody, or antigen-binding fragment thereof, wherein at least one symptom associated with osteoarthritis is prevented, ameliorated or improved.Type: GrantFiled: October 10, 2012Date of Patent: January 28, 2014Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Lynn MacDonald, Richard Torres, Marc R. Morra, Joel H. Martin, Joel C. Reinhardt, Paul Tiseo
-
Patent number: 8613927Abstract: A human antibody or antigen-binding fragment of an antibody which specifically binds human nerve growth factor (NGF) with KD of 5 pM or less, as measured by surface plasmon resonance, wherein the antibody or fragment thereof binds human NGF with an affinity of about 2-10-fold higher than the antibody or fragment binds rat and mouse NGF. The antibodies are useful in treating pain, including inflammatory pain, post-operative incision pain, neuropathic pain, fracture pain, osteoporotic fracture pain, post-herpetic neuralgia, osteoarthritis, rheumatoid arthritis, cancer pain, pain resulting from burns, gout joint pain, as well as diseases, such as hepatocellular carcinoma, breast cancer, and liver cirrhosis.Type: GrantFiled: February 28, 2012Date of Patent: December 24, 2013Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Lynn MacDonald, Richard Torres, Marc R. Morra, Joel H. Martin, Joel C. Reinhardt
-
Patent number: 8425907Abstract: The present invention provides methods for treating pruritus by blocking human protease activated receptor-2 (PAR2) activity. The methods of the invention can be used to treat pruritus associated with atopic dermatitis, psoriasis, burn scarring, hypertrophic scarring, keloids, renal failure or hepatic failure. The methods of the invention include administering an antibody or antigen-binding fragment thereof that specifically binds human PAR2.Type: GrantFiled: December 14, 2011Date of Patent: April 23, 2013Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Lynn MacDonald, Andrew J. Murphy, Nicholas J. Papadopoulos, Marc R. Morra, Robert R. Salzler, Michael L. LaCroix-Fralish
-
Patent number: 8309088Abstract: Methods are disclosed for treating osteoarthritis in a human subject in need thereof, comprising administering to the subject a therapeutically effective amount of an anti-human NGF antibody, or antigen-binding fragment thereof, wherein at least one symptom associated with osteoarthritis is prevented, ameliorated or improved.Type: GrantFiled: September 23, 2010Date of Patent: November 13, 2012Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Lynn MacDonald, Richard Torres, Marc R. Morra, Joel H. Martin, Joel C. Reinhardt, Paul Tiseo
-
Publication number: 20120164688Abstract: A human antibody or antigen-binding fragment of an antibody which specifically binds human nerve growth factor (NGF) with KD of 5 pM or less, as measured by surface plasmon resonance, wherein the antibody or fragment thereof binds human NGF with an affinity of about 2-10-fold higher than the antibody or fragment binds rat and mouse NGF. The antibodies are useful in treating pain, including inflammatory pain, post-operative incision pain, neuropathic pain, fracture pain, osteoporotic fracture pain, post-herpetic neuralgia, osteoarthritis, rheumatoid arthritis, cancer pain, pain resulting from burns, gout joint pain, as well as diseases, such as hepatocellular carcinoma, breast cancer, and liver cirrhosis.Type: ApplicationFiled: February 28, 2012Publication date: June 28, 2012Applicant: Regeneron Pharmaceuticals, Inc.Inventors: Lynn MACDONALD, Richard Torres, Marc R. Morra, Joel H. Martin, Joel C. Reinhardt